Lasmiditan is a member of a novel drug class called "ditans".
Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5‑HT1F receptors expressed in the trigeminal nerve pathway.Learn More About Lasmiditan
Unmet Needs of Migraine Patients:
- Treatment Options for Those with Cardiovascular Risk Factors and/or Cardiovascular Disease
- Dissatisfaction with Current Therapy
- Headache Disability
- Overuse of Opioids and Barbiturates
- Too Many Emergency Room visits
Lasmiditan does not interact with vasoconstrictor 5‑HT1B/1D receptors activated by triptans.
No evidence of drug-related cardiovascular adverse effects or chest symptoms in the previous seven clinical studies.Learn More About Lasmiditan
Seven clinical studies provide Proof of Concept in the acute treatment of migraine attacks.
Provided relief of nausea, photophobia (sensitivity to light) and phonophobia. (sensitivity to sound).